Because of these effects, GLP‐1 is an attractive target for the treatment of both type 2 diabetes and obesity, and GLP‐1‐based drugs are now used for both indications (Zander et al. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.